var data={"title":"Clindamycin (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clindamycin (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/387892?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clindamycin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Clindamycin (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=clindamycin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clindamycin (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8007987\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Colitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <i>Clostridium difficile</i>&ndash;associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of <i>C. difficile</i>.</p>\n        <p style=\"text-indent:-4em;margin-left:4em;\">Because clindamycin therapy has been associated with severe colitis, which may end fatally, reserve it for serious infections for which less toxic antimicrobial agents are inappropriate. Do not use clindamycin in patients with nonbacterial infections, such as most upper respiratory tract infections.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">\n          <i>C. difficile</i> produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of <i>C. difficile</i> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <i>C. difficile</i> may need to be discontinued. Institute appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <i>C. difficile</i>, and surgical evaluation as clinically indicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008032\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cleocin;</li>\n      <li>Cleocin in D5W;</li>\n      <li>Cleocin Phosphate;</li>\n      <li>CLIN Single Use</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008033\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Clindamycin;</li>\n      <li>Auro-Clindamycin;</li>\n      <li>Ava-Clindamycin;</li>\n      <li>Clindamycin Injection;</li>\n      <li>Clindamycin Injection SDZ;</li>\n      <li>Clindamycin Injection, USP;</li>\n      <li>Clindamycin IV Infusion;</li>\n      <li>Clindamycine;</li>\n      <li>Dalacin C;</li>\n      <li>Mylan-Clindamycin;</li>\n      <li>PMS-Clindamycin;</li>\n      <li>Riva-Clindamycin;</li>\n      <li>Teva-Clindamycin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10533166\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Anaerobic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442269\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP], 2012): IM, IV, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &le;14 days: 5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 15-28 days: 5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Body weight 1-2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &le;7 days: 5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 8-28 days: 5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Body weight &gt;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &le;7 days: 5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 8-28 days: 5 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Manufacturer&rsquo;s labeling:</b> Term infant: IM, IV: 15 to 20 mg/kg/day divided every 6 to 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10533179\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=clindamycin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Clindamycin (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Infants, Children, and Adolescents 1 month to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing: 20 to 40 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA-directed dosing: 350 to 450 mg/m<sup>2</sup>/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing (<i>Red Book</i> [AAP], 2012): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild to moderate infections: 20 mg/kg/day divided every 8 hours; maximum daily dose: 1800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe infections: 40 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 2700 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer&rsquo;s labeling: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hydrochloride salt (capsule): 8 to 20 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Palmitate salt (solution): 8 to 25 mg/kg/day divided every 6 to 8 hours; minimum dose: 37.5 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing (<i>Red Book</i> [AAP]; 2012): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Mild to moderate infections: 10 to 25 mg/kg/day divided every 8 hours; maximum daily dose: 1800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe infections: 30 to 40 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 1800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Babesiosis:</b> Infants, Children, and Adolescents: Oral: 20 to 40 mg/kg/day divided every 8 hours for 7 to 10 days plus quinine; maximum single dose: 600 mg (<i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial endocarditis prophylaxis for dental and upper respiratory procedures in penicillin-allergic patients</b> (<i>Red Book</i> [AAP], 2012; Wilson, 2007): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 20 mg/kg 30 minutes before procedure; maximum single dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 20 mg/kg 1 hour before procedure; maximum single dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Infant, Children, and Adolescents: Oral: 10 mg/kg/dose 3 times daily; maximum dose: 600 mg/dose (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: <b>Note:</b> Not recommended for community-acquired infections due to increasing <i>Bacteroides fragilis</i> resistance: 20 to 40 mg/kg/day divided every 6 to 8 hours in combination with gentamicin or tobramycin (Solomkin, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria, treatment:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated:</i> Oral: 20 mg/kg/day divided every 8 hours for 7 days plus quinine (CDC, 2011; <i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Severe:</i> IV: Loading dose: 10 mg/kg once followed by 15 mg/kg/day divided every 8 hours plus IV quinidine gluconate; switch to oral therapy (clindamycin and quinine, see above) when able for total treatment duration of 7 days. <b>Note:</b> Quinine duration is region specific; consult CDC for current recommendations (CDC, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteomyelitis, septic arthritis, due to MRSA:</b> Infants, Children, and Adolescents: IV, Oral: 40 mg/kg/day divided every 6 to 8 hours for at least 4 to 6 weeks (osteomyelitis) or 3 to 4 weeks (septic arthritis) (Liu, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute:</b> Infants &ge;6 months, Children, and Adolescents: Oral: 30 to 40 mg/kg/day divided every 8 hours; administer with or without a third generation cephalosporin (AAP [Lieberthal, 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis</i> (Warady [ISPD 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Invasive dental procedures: Oral: 20 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gastrointestinal or genitourinary procedures: IV: 10 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i> Intraperitoneal, continuous: Loading dose: 300 mg per liter of dialysate; maintenance dose: 150 mg per liter; <b>Note:</b> 125 mg/liter has also been recommended as a maintenance dose (Aronoff, 2007; Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>AHA guidelines</i> (Gerber, 2009): Children and Adolescents: Oral: 20 mg/kg/day in divided doses 3 times daily for 10 days; maximum single dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>IDSA guidelines</i> (Shulman, 2012): Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment and primary prevention of rheumatic fever: 21 mg/kg/day in divided doses 3 times daily for 10 days; maximum single dose: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment of chronic carriers: 20 to 30 mg/kg/day in divided doses 3 times daily for 10 days; maximum single dose: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumococcal disease, invasive:</b> Infants, Children, and Adolescents: IV: 25 to 40 mg/kg/day divided every 6 to 8 hours (<i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pneumocystis jirovecii </i></b>\n      <b>(formerly</b>\n      <b>\n        <i> carnii)</i></b>\n      <b> pneumonia (PCP):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non HIV-exposed/-positive</i> (<i>Red Book</i> [AAP], 2012): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate disease: Oral: 10 mg/kg 3 to 4 times daily for 21 days; in combination with other agents; maximum single dose: 450 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe disease: IV: 15 to 25 mg/kg 3 to 4 times daily for 21 days; give with pentamidine or primaquine; maximum single dose: 600 mg. May switch to oral dose after clinical improvement.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive:</i> Adolescents (DHHS [adult], 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate disease: Oral: 300 mg every 6 hours <b>or</b> 450 mg every 8 hours with primaquine for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe disease:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 300 mg every 6 hours <b>or</b> 450 mg every 8 hours with primaquine for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 600 mg every 6 hours <b>or</b> 900 mg every 8 hours with primaquine for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Community-acquired pneumonia (CAP)</i> (IDSA/PIDS, Bradley, 2011): Infants &ge;3 months, Children, and Adolescents: <b>Note:</b> In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate to severe infection: IV: 40 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infection, step-down therapy: Oral: 30 to 40 mg/kg/day divided every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MRSA pneumonia:</i> IV: 40 mg/kg/day divided every 6 to 8 hours for 7 to 21 days (Liu, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, acute bacterial:</b> Children and Adolescents: Oral: 30 to 40 mg/kg/day divided every 8 hours with concomitant cefixime or cefpodoxime for 10 to 14 days. <b>Note:</b> Recommended in patients with nontype I penicillin allergy, after failure to initial therapy, or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infection:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Impetigo:</i> Oral: 10 to 20 mg/kg/day in divided doses 3 times daily; treatment duration: 7 days; maximum single dose: 400 mg (Stevens, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MRSA infection</i> (Liu, 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cellulitis, nonpurulent or purulent: Oral: 40 mg/kg/day divided every 6 to 8 hours; maximum single dose: 450 mg; treatment duration based on clinical response, usually 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Complicated SSTI infection: IV, Oral: 40 mg/kg/day divided every 6 to 8 hours for 7 to 14 days; maximum single dose range: 450 to 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MSSA infection</i> (Stevens, 2005): Duration of treatment dependent upon site and severity of infection; cellulitis and abscesses typically require 5 to 10 days of therapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 25 to 40 mg/kg/day in divided doses 3 times daily; maximum single dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 10 to 20 mg/kg/day in divided doses 3 times daily; maximum single dose: 450 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 10 mg/kg 30 to 60 minutes prior to the procedure; may repeat in 6 hours; maximum single dose: 900 mg (Bratzler, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Toxoplasmosis (HIV-exposed/positive or hematopoietic cell transplantation recipients):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children (CDC, 2009; <i>Red Book</i> [AAP], 2012; Tomblyn, 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment, HIV-exposed/-positive:</i> IV, Oral: 5 to 7.5 mg/kg/dose 4 times daily with pyrimethamine and leucovorin; maximum single dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Secondary prevention:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: Oral: 7 to 10 mg/kg/dose every 8 hours and pyrimethamine plus leucovorin; maximum single dose: 600 mg (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hematopoietic cell transplantation recipients: Oral: 5 to 7.5 mg/kg/dose every 6 hours and pyrimethamine plus leucovorin; maximum single dose: 450 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents (DHHS [adult], 2013; <i>Red Book</i> [AAP], 2012; Tomblyn, 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment:</i> Oral, IV: 600 mg every 6 hours with pyrimethamine and leucovorin for at least 6 weeks; longer if clinical or radiologic disease is extensive or response is incomplete</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Secondary prevention: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: Oral: 600 mg every 8 hours with pyrimethamine and leucovorin</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hematopoietic cell transplantation recipients: Oral: 300 to 450 mg every 6 to 8 hours with pyrimethamine and leucovorin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 150 to 450 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 600 to 2,700 mg/day in 2 to 4 divided doses; up to 4,800 mg IV daily may be used in life-threatening infections</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amnionitis:</b> IV: 450 to 900 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial vaginosis:</b> Oral: 300 mg twice daily for 7 days (CDC, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cellulitis due to MRSA:</b> Oral: 300 to 450 mg 3 times daily for 5 to 10 days (Liu, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Complicated skin/soft tissue infection due to MRSA:</b> IV, Oral: 600 mg 3 times daily for 7 to 14 days (Liu, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis prophylaxis</b> (Wilson, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 600 mg 30 to 60 minutes before procedure with no follow-up dose needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 600 mg 30 to 60 minutes before procedure. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gangrenous pyomyositis:</b> IV: 900 mg every 8 hours with penicillin G</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Group B Streptococcus (neonatal prophylaxis):</b> IV: 900 mg every 8 hours until delivery (CDC, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria, severe:</b> IV: Load: 10 mg/kg followed by 15 mg/kg/day divided every 8 hours plus IV quinidine gluconate; switch to oral therapy (clindamycin plus quinine) when able for total clindamycin treatment duration of 7 days (<b>Note:</b> Quinine duration is region-specific, consult CDC for current recommendations) (CDC, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria, uncomplicated treatment:</b> Oral: 20 mg/kg/day divided every 8 hours for 7 days plus quinine (CDC, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Orofacial/peripharyngeal space infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 150 to 450 mg every 6 hours for at least 7 days; maximum daily dose: 1800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 600 to 900 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteomyelitis due to MRSA:</b> IV, Oral: 600 mg 3 times daily for a minimum of 8 weeks (some experts combine with rifampin) (Liu, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease:</b> IV: 900 mg every 8 hours with gentamicin (conventional or single daily dosing); 24 hours after clinical improvement may convert to oral clindamycin 450 mg 4 times daily or oral doxycycline to complete 14 days of total therapy. Avoid doxycycline if tubo-ovarian abscess is present (CDC, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis, group A streptococci</b> (IDSA, Shulman, 2012): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute treatment in penicillin-allergic patients: 21 mg/kg/day divided every 8 hours for 10 days; maximum single dose: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic carrier treatment: 20 to 30 mg/kg/day divided every 8 hours for 10 days; maximum single dose: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pneumocystis jirovecii</i></b>\n      <b> pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 600 mg every 6 hours <b>or</b> 900 mg every 8 hours with primaquine for 21 days (DHHS [adult], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 300 mg every 6 hours <b>or</b> 450 mg every 8 hours with primaquine for 21 days (DHHS [adult], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia due to MRSA:</b> IV, Oral: 600 mg 3 times daily for 7 to 21 days (Liu, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia:</b> <b>Note:</b> In general, patients with prosthetic joint implants do not require prophylactic antibiotics prior to dental procedures. In planning an invasive oral procedure, dental consultation with the patient's orthopedic surgeon may be advised to review the risks of infection (Sollecito 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 600 mg 1 hour prior to procedure (ADA, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 600 mg 1 hour prior to procedure (for patients unable to take oral medication) (ADA, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prosthetic joint infection</b> (Osmon, 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic antimicrobial suppression, staphylococci (oxacillin-susceptible): Oral: 300 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cutibacterium acnes, treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 300 to 450 mg every 6 hours for 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 600 to 900 mg every 8 hours for 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Septic arthritis due to MRSA:</b> IV, Oral: 600 mg 3 times daily for 3 to 4 weeks (Liu, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Toxic shock syndrome:</b> IV: 900 mg every 8 hours with penicillin G or ceftriaxone</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Toxoplasmosis encephalitis, HIV-exposed/-positive</b> (DHHS [adult], 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Oral, IV: 600 mg every 6 hours with pyrimethamine and leucovorin for at least 6 weeks; longer if clinical or radiologic disease is extensive or response is incomplete</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Secondary prevention: Oral: 600 mg every 8 hours with pyrimethamine and leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No adjustment required. Not dialyzable (0% to 5%).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No adjustment required. Use caution with severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008168\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin: 75 mg, 150 mg [contains brilliant blue fcf (fd&amp;c blue #1), tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin: 300 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg, 150 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as phosphate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CLIN Single Use: 300 mg/2 mL [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as phosphate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 300 mg/2 mL (2 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL) [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 900 mg/6 mL (6 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 900 mg/6 mL (6 mL); 9 g/60 mL (60 mL) [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL); 9000 mg/60 mL (60 mL); 9 g/60 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as phosphate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin in D5W: 300 mg/50 mL (50 mL); 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL) [contains edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin Phosphate: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL) [contains benzyl alcohol, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/50 mL (50 mL); 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL); 150 mg/mL (2 mL); 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL); 300 mg/50 mL in NaCl 0.9% (50 mL); 600 mg/50 mL in NaCl 0.9% (50 mL); 900 mg/50 mL in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral, as palmitate hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin: 75 mg/5 mL (100 mL) [contains ethylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg/5 mL (100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008035\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10533497\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Capsule should be taken with a full glass of water to avoid esophageal irritation; shake oral solution well before use; may administer with or without meals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer undiluted deep IM; rotate sites. Do not exceed 600 mg in a single injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Infuse over at least 10 to 60 minutes, at a rate not to exceed 30 mg/minute; hypotension and cardiopulmonary arrest have been reported following rapid IV administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008093\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not refrigerate the reconstituted  oral solution (it will thicken); the solution is stable for 2 weeks at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Store intact vials and premixed bags at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Infusion solution in NS or D5W solution is stable for 16 days at room temperature, 32 days refrigerated, or 8 weeks frozen. After initial use, discard any unused portion of vial after 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10533167\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of infections involving the respiratory tract, skin and soft tissue, and female pelvis and genital tract; sepsis and intra-abdominal infections due to susceptible organisms (FDA approved in all ages); has also been used for endocarditis prophylaxis, preoperative prophylaxis, and prophylaxis of peritonitis in patients with peritoneal dialysis catheters undergoing invasive dental procedures, gastrointestinal or genitourinary procedures, or treatment of peritonitis, and exit site and tunnel infections in patients with peritoneal dialysis catheters and  treatment of babesiosis and malaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8007988\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cleocin may be confused with bleomycin, Clinoril, Cubicin, Lincocin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clindamycin may be confused with clarithromycin, Claritin, vancomycin, lincomycin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008066\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypotension (rare; IV administration), thrombophlebitis (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Metallic taste (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme (rare), exfoliative dermatitis (rare), maculopapular rash, pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis, urticaria, vesiculobullous dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, antibiotic-associated colitis, <i>Clostridium difficile</i> associated diarrhea, diarrhea, esophageal ulcer, esophagitis, nausea, pseudomembranous colitis, unpleasant taste (IV), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Azotemia, oliguria, proteinuria, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia (transient), neutropenia (transient), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactic shock, anaphylactoid reaction (rare), anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: DRESS syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Abscess at injection site (IM), induration at injection site (IM), irritation at injection site (IM), pain at injection site (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Polyarthritis (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal insufficiency (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008053\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to clindamycin, lincomycin, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Oral clindamycin: Infants &lt;30 days of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008062\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Colitis: <b> [US Boxed Warning]: Can cause severe and possibly fatal colitis.</b><b> Should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. Hypertoxin-producing strains of</b> <b><i>C. difficile</i></b> <b> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. </b><b><i>C. difficile</i></b><b>-associated diarrhea (CDAD) must be considered in all patients who present with diarrhea following antibiotic use. CDAD has been observed &gt;2 months postantibiotic treatment. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against </b><b><i>C. difficile</i></b> <b> may need to be discontinued. Institute appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of </b><b><i>C. difficile</i></b><b>, and surgical evaluation as clinically indicated.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe hypersensitivity reactions, including severe skin reactions (eg, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN]), some fatal, and anaphylactic reactions, including anaphylactic shock, have been reported. Permanently discontinue treatment and institute appropriate therapy if these reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Use may result in overgrowth of nonsusceptible organisms, particularly yeast. Should superinfection occur, appropriate measures should be taken as indicated by the clinical situation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Use with caution in patients with a history of GI disease, particularly colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with moderate to severe liver disease, however, when administered at every-8-hour intervals, drug accumulation is rare. Monitor hepatic enzymes periodically as dosage adjustments may be necessary in patients with severe  liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atopic patients: Use with caution in atopic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: A subgroup of older patients with associated severe illness may tolerate diarrhea less well. Monitor carefully for changes in bowel frequency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tartrazine: Some products may contain tartrazine (FD&amp;C yellow no. 5), which may cause allergic reactions in certain individuals. Allergy is frequently seen in patients who also have an aspirin hypersensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration (IV):  Do not inject IV undiluted as a bolus. Product should be diluted in compatible fluid and infused over 10 to 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not appropriate for use in the treatment of meningitis due to inadequate penetration into the CSF.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299057\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008069\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15953&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Clindamycin (Systemic). Refer to the specific clindamycin (systemic) - rifampin drug interaction monograph for information concerning that combination.<b> Exceptions: </b>RifAMPin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kaolin: May decrease the absorption of Lincosamide Antibiotics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008048\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Clindamycin crosses the placenta and can be detected in the cord blood and fetal tissue (Philipson 1973; Weinstein 1976). Clindamycin injection contains benzyl alcohol which may also cross the placenta. Clindamycin pharmacokinetics are not affected by pregnancy (Philipson 1976; Weinstein 1976). Clindamycin is recommended for use in pregnant women for the prophylaxis of group B streptococcal disease in newborns (alternative therapy) (ACOG 485, 2011); prophylaxis and treatment of <i>Toxoplasma gondii</i> encephalitis (alternative therapy), or <i>Pneumocystis pneumonia</i> (PCP) (alternative therapy) (HHS [OI adult 2015]); bacterial vaginosis (CDC [Workowski 2015]); anthrax (Meaney-Delman 2014); or malaria (CDC 2013). Clindamycin is also one of the antibiotics recommended for prophylactic use prior to cesarean delivery and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (ACOG 120, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10533498\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for changes in bowel frequency; during prolonged therapy, monitor CBC with differential, platelet count, and hepatic and renal function tests periodically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008096\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008098\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral, hydrochloride: Rapid (90%); clindamycin palmitate must be hydrolyzed in the GI tract before it is active</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributed in body fluids and tissues; no significant levels in CSF, even with inflamed meninges</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Biologically inactive clindamycin phosphate (intravenous formulation) is rapidly converted to active clindamycin. Clindamycin is metabolized predominantly by CYP3A4, with minor contribution by CYP3A5, to form clindamycin sulfoxide (major metabolite) and N-desmethylclindamycin (minor metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: Premature: 8.7 hours; Full-term: 3.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 month to 1 year: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: ~2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elderly (oral) ~4 hours (range: 3.4 to 5.1 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Within 60 minutes; IM: 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~10%) and feces (3.6%) as active drug and metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8008170\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cleocin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $562.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $1,104.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $2,243.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Clindamycin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (200): $144.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $119.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $371.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (CLIN Single Use Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (1): $538.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cleocin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/50 mL (50 mL): $13.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/50 mL (50 mL): $20.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/50 mL (50 mL): $25.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cleocin Phosphate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 g/60 mL (60 mL): $27.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (2 mL): $2.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/4 mL (4 mL): $3.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/6 mL (6 mL): $5.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cleocin Phosphate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (2 mL): $4.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/4 mL (4 mL): $5.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/6 mL (6 mL): $6.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clindamycin Phosphate in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/50 mL (50 mL): $9.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/50 mL (50 mL): $14.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/50 mL (50 mL): $18.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clindamycin Phosphate in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/50 mL 0.9% (50 mL): $8.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/50 mL 0.9% (50 mL): $12.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/50 mL 0.9% (50 mL): $15.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clindamycin Phosphate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9 g/60 mL (60 mL): $20.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (2 mL): $2.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/4 mL (4 mL): $3.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/6 mL (6 mL): $5.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clindamycin Phosphate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/2 mL (2 mL): $4.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg/4 mL (4 mL): $5.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 mg/6 mL (6 mL): $5.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cleocin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg/5 mL (100 mL): $163.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Clindamycin Palmitate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg/5 mL (100 mL): $62.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961961\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acnocin (TH);</li>\n      <li>Albiotin (ID);</li>\n      <li>Aledo Gel (TW);</li>\n      <li>BB (TW);</li>\n      <li>Chinacin-T (TH);</li>\n      <li>Cleocin (BB);</li>\n      <li>Cleocin HCl (AU, PK, TW);</li>\n      <li>Cleocin T (TR, TW);</li>\n      <li>Clicin (VN);</li>\n      <li>Clidets (VE);</li>\n      <li>Climadan (ID, SG);</li>\n      <li>Climax (BD);</li>\n      <li>Clinacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Clinbac (PH);</li>\n      <li>Clinbercin (ID);</li>\n      <li>Clincin (TW);</li>\n      <li>Clinda (DE);</li>\n      <li>Clinda-P (TH);</li>\n      <li>Clindabact (LK);</li>\n      <li>Clindac-A (IN);</li>\n      <li>Clindacid (PY);</li>\n      <li>Clindacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PE, SA, SY, YE);</li>\n      <li>Clindagen (PH);</li>\n      <li>Clindal (PH);</li>\n      <li>Clindala (ID);</li>\n      <li>Clindalin (TH);</li>\n      <li>Clindatec (PH);</li>\n      <li>Clindavid (TH);</li>\n      <li>Clindox (JO);</li>\n      <li>Clinott (TH);</li>\n      <li>Cliz (PH);</li>\n      <li>Dacin (SG);</li>\n      <li>Daclin (BD);</li>\n      <li>Daklin (PH);</li>\n      <li>Dalacin (AE, BD, ES, HU, IE, IS, JO, QA, TH, UA);</li>\n      <li>Dalacin C (AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DK, DO, EC, EE, EG, ET, GB, GH, GM, GN, GR, GT, HK, HN, HR, ID, IE, IL, IN, IQ, IR, IT, KE, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PL, PT, QA, RO, SA, SC, SD, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TZ, UA, UG, UY, VN, YE, ZA, ZM, ZW);</li>\n      <li>Dalacine (FR);</li>\n      <li>Dalaclin (PH);</li>\n      <li>Dalamed (PH);</li>\n      <li>Dalcap (IN);</li>\n      <li>Damicine (CO);</li>\n      <li>Damiclin V (CO);</li>\n      <li>Euroclin (EC);</li>\n      <li>Fullgram (KR);</li>\n      <li>Jutaclin (DE);</li>\n      <li>Klimicin (CZ);</li>\n      <li>Klincyn (PH);</li>\n      <li>Klinda RX (TH);</li>\n      <li>Klindamycin (TH);</li>\n      <li>Lacin (TH);</li>\n      <li>Lanacin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Lando (ID);</li>\n      <li>Librodan (ID);</li>\n      <li>Lindacin (MY, TW);</li>\n      <li>Luoqing (CN);</li>\n      <li>Neotasin (KR);</li>\n      <li>Nildacin (ID);</li>\n      <li>Peldacyn (PH);</li>\n      <li>Potecin (PH);</li>\n      <li>Qualiclinda (HK);</li>\n      <li>Queritan (PY);</li>\n      <li>Tidact (LK, PH, TW);</li>\n      <li>Todacin (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2011;117(6):1472-1483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 485: Prevention of Early-Onset Group B Streptococcal Disease in Newborns,&quot; <i>Obstet Gynecol</i>, 2011, 117(4):1019-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/21422882/pubmed\" target=\"_blank\" id=\"21422882\">21422882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association (ADA) and American Academy of Orthopedic Surgeons, &quot;Antibiotic Prophylaxis for Dental Patients With Total Joint Replacements,&quot; <i>J Am Dent Assoc</i>, 2003, 134(7):895-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/12892448/pubmed\" target=\"_blank\" id=\"12892448\">12892448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p. 55, 149.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Diagnosis and Treatment of Malaria.&quot; Available at <a href=\"http://www.cdc.gov/malaria/diagnosis_treatment/index.html\" target=\"_blank\">http://www.cdc.gov/malaria/diagnosis_treatment/index.html</a>. Date accessed: October 21, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines From CDC, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010a, 59(RR-10):1-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/21088663/pubmed\" target=\"_blank\" id=\"21088663\">21088663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Sexually Transmitted Diseases Treatment Guidelines, 2010,&quot; <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Treatment of Malaria Guidelines for Clinicians 2013. Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf%20\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al, &quot;Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute <i>Streptococcal pharyngitis</i>: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,&quot; <i>Circulation</i>, 2009, 119(11):1541-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/19246689/pubmed\" target=\"_blank\" id=\"19246689\">19246689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. March 1, 2016. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al, &quot;The Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &quot;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary,&quot; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann CF, &quot;Clindamycin and Breast-Feeding,&quot; <i>Pediatrics</i>, 1980, 66(6):1030-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/7454470/pubmed\" target=\"_blank\" id=\"7454470\">7454470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014;20(2). Available at http://dx.doi.org/10.3201/eid2002.130611</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A, Sabath LD, and Charles D, &quot;Transplacental Passage of Erythromycin and Clindamycin,&quot; <i>N Engl J Med</i>, 1973, 288(23):1219-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/4700555/pubmed\" target=\"_blank\" id=\"4700555\">4700555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &quot;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &quot;Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/PMID:20034345[PubMed - indexed for MEDLINE] Free full text /pubmed\" target=\"_blank\" id=\"PMID:20034345[PubMed - indexed for MEDLINE] Free full text \">PMID:20034345[PubMed - indexed for MEDLINE] Free full text </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al, &quot;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&quot; <i>Clin Infect Dis</i>, 2005, 41(10):1373-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/16231249/pubmed\" target=\"_blank\" id=\"16231249\">16231249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. <i>J Am Dent Assoc</i>. 2015;146(1):11-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/25569493 /pubmed\" target=\"_blank\" id=\"25569493 \">25569493 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al, &quot;Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective,&quot; <i>Biol Blood Marrow Transplant</i>, 2009, 15(10):1143-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i> Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinstein AJ, Gibbs RS, and Gallagher M, &quot;Placental Transfer of Clindamycin and Gentamicin in Term Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 1976, 124(7):688-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/943947/pubmed\" target=\"_blank\" id=\"943947\">943947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &quot;Prevention of Infective Endocarditis. Guidelines From the American Heart Association,&quot; <i>Circulation</i>, 2007, 115:1-20.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clindamycin-systemic-pediatric-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15953 Version 226.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8007987\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8008032\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8008033\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10533166\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442269\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10533179\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8008168\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8008035\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10533497\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8008093\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10533167\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8007988\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8008066\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8008053\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8008062\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299057\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8008069\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8008048\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10533498\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8008096\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8008098\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8008170\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961961\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15953|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clindamycin-systemic-drug-information\" class=\"drug drug_general\">Clindamycin (systemic): Drug information</a></li><li><a href=\"topic.htm?path=clindamycin-systemic-patient-drug-information\" class=\"drug drug_patient\">Clindamycin (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}